A paper on the clinical usefulness of Vcheck CRP in dogs infected with heartworms has been published in the international journal, Veterinary world (IF 2.11). See the attached file for full paper. Canine filariasis is a prominent mosquito-borne disease which is caused by several species of filarial worms, including Dirofilaria immitis. The pathophysiological response to infection is mainly due to the filaria lifecycle. In this study, blood samples were collected from 980 dogs who have visited animal hospitals and all samples were tested to determine the presence of microfilaria. In positive samples, the serum protein profiles and CRP concentrations using the Vcheck CRP 2.0 were examined. The average CRP concentrations of dogs infected with only D. immitis was 69.6 (13.6-116.9) mg/L. A dog infected with both D. immitis and B. pahangi had very high CRP concentrations (>200 mg/L). The total protein, β2 globulin, and γ globulin levels increased, while albumin levels and albumin-to-globulin (A/G) ratios were significantly reduced. In heartworm disease, adult worms are localized in the pulmonary arteries, which induces endothelial damage or proliferative endocarditis. Chronic inflammation leads to elevated CRP concentrations and hyperglobulinemia. According to this study, the serum protein profiles and CRP concentrations in canine filariasis can reflect the health status of infected dogs. In particular, the CRP concentrations in dogs infected with D. immitis were significantly high, proving its usefulness as a marker of inflammation. C-reactive protein (CRP), a major acute protein in dogs, is elevated in response to inflammatory stimuli, which can be useful in various inflammatory situations such as infections, tumors, acute pancreatitis, and surgery. Vcheck CRP 2.0 can be quantitatively measured using a fluorescent immunoassay analyzer, Vcheck, and can be tested using a small amount of sample (a serum or plasma 5ul). It also has a wide measurement range of 10 to 200 mg/L, making it suitable for monitoring responses during treatment. Learn more
A paper using Vcheck CPV Ab testing has been published with results proving that regular vaccinations under the WSAVA guidelines increase the protection rate against parvovirus. - [Related document] Evaluation materials Canine parvovirosis is a systemic disease caused by CPV-2 (canine parvovirus type 2). Typical symptoms of parvovirus include lack of appetite, vomiting, and bloody diarrhea.The most effective way to prevent the parvovirus is prophylactic vaccination, and according to the WSAVA guidelines, it is recommended that booster vaccines be performed not more often than every 3 years after the initial puppy vaccination. Based on the history of the vaccination against CPV, the study population was divided into three groups: - Group I (n=59): Dogs regularly vaccinated against the disease according to WSAVA guidelines- Group II (n=77): Dogs that completed the full course of CPV immunization as puppies but have not received a booster dose in the past three years- Group III (n=64): Dogs that have not received vaccination against parvovirus in their lifetime Statistical analysis showed a significantly greater number of dogs with high titers of antibodies against CPV of HI ≥ 80 in Group I (86%) compared to Group II (73%), and Group III (72%). Table 1. Values of antibody titers in HI test for CPV in dogs in each group Gender and race were not found to have an influence over the value of antibody titers against CPV. Regular vaccinations by WSAVA recommendations increase protection against CPV, as evidenced by the lowest percentage of dogs with HI < 80 in Group I, which were regularly vaccinated at least every 3 years. Additionally, the presence of dogs with high antibody titers against CPV in Group III indicates widespread contamination of the pathogen within the environment. Bionote's immunofluorescence analyzer, Vcheck, is designed to generate fast and accurate diagnoses for in-clinic testing through its automative blood testing system that can run 24 quantitative and semi-qualitative tests (NT-proBNP, SDMA, D-dimer, CRP, SAA, cPL, fPL, cCortisol, T4, TSH, Progesterone, and Antibody titers).
Bionote developed a nasal swab test version of the COVID-19 antigen rapid diagnostic kit, in addition to the existing nasopharyngeal swab test. This new version has also obtained Certification of EU product notification as well. Antigen rapid diagnostic kit is a widely used screening and diagnosing method for infectious diseases such as influenza in hospitals. The test procedure for a rapid kit is simple, fast, and efficient, requiring only 15 to 30 minutes without the need for any additional equipment. With such efficiency, antigen tests enable more massive testing with a faster diagnosis compared to a molecular diagnostic method such as a PCR test. The NowCheck COVID-19 Ag Test, which is manufactured and sold by Bionote, is a diagnostic kit that quickly determines SARS-CoV-2 infection (COVID-19). Until now, it previously came only with nasopharyngeal swab specimens, but a new nasal swab type has recently been added. A clinical evaluation conducted in Brazil between July and August confirmed an excellent performance of 89.2% (91/102) sensitivity and 97.3% (290/298) specificity. In particular, the sensitivity was found to be up to 92.2% in patients when the days from symptom onset were ≤ 7 days. While most conventional COVID-19 antigen tests are performed by inserting a swab deep into a nostril to collect the specimen from the nasopharynx, it may cause discomfort among the patients during the collection process. That is why patients will find Bionote's newly developed nasal swab version relatively easier to use compared to the previous nasopharyngeal swab test. The nasal cavity is located outward compared to the nasopharynx, making it easier to collect the specimens with less discomfort and thus requiring less proficiency from inspectors. Since there is no effective treatment for COVID-19, a more active response to the COVID-19 pandemic should be made possible with rapid diagnostic kits. CE certified NowCheck COVID-19 test offers not only accurate results, but also more swab options for the consumers to choose from. For those who are interested in NowCheck COVID-19 Tests, please contact your local distributor or mail to [bionote@bionote.co.kr].